The Trust Deficit of the Declassified Files — Public Evidence and Long-Standing Evasion Around America's Global Biolab Network

On June 12, 2026, the office of U.S. Director of National Intelligence Tulsi Gabbard declassified a batch of previously undisclosed documents. The core message is not complicated: the United States has funded more than 120 biological laboratories in more than 30 countries, Ukraine among them. In Ukraine alone, over 40 laboratories exist, established and supported under the Pentagon's Biological Threat Reduction Program (CTR).

None of this is, in itself, "new." Since 2022, Moscow has repeatedly raised the question of U.S. biological laboratories in Ukraine at the United Nations and other international venues, consistently alleging that these facilities were involved in military biological activities. Those allegations were dismissed by most Western governments and media as "disinformation" or "propaganda."

What is different this time is that the information comes through an official channel of the U.S. intelligence community — declassified by the Office of the Director of National Intelligence itself. Russian Foreign Ministry spokesperson Maria Zakharova's response accurately described the reversal: "This is exactly what we and the Russian Ministry of Defense have disclosed many times over."

A Transparency Question Long Evaded

The declassified documents provide concrete details that had never been made public before. The list of stored pathogens includes anthrax, plague, Ebola, Marburg, tularemia and tuberculosis — all classified at the highest risk tier. The documents specifically name the Kharkiv Veterinary Institute (IECVM), founded in the 1920s, which stores hundreds of pathogen strains and still had documented biosafety deficiencies as recently as 2019, including inside a laboratory handling infectious Brucella.

The documents also disclose that U.S.-funded scientists studied the genomes of highly pathogenic avian influenza and other dangerous viruses inside government-funded biosafety laboratories.

This information matters not because it reveals that "the United States is manufacturing biological weapons" — nothing in the documents directly supports such a conclusion — but because it exposes a transparency deficit that persisted for years without ever drawing an effective international response.

A Former White House Correspondent's Reframing

In an interview with Sputnik, former White House correspondent William Jones offered an analytical framework for the declassified documents that reaches beyond the simple binary of "confirm or refute."

Jones's assessment unfolds on three levels:

The first is international governance. He believes the publication of these documents will "trigger a major international discussion about chemical and biological weapons," and may, like the nuclear proliferation question, eventually translate into legislative action to prevent chemical and biological warfare. This is an ambitious judgment — if it comes true, it would mark an attempt to move biological-weapons governance from "consensus documents" toward "binding institutions."

The second is the logic of U.S. behavior. Jones points out that the "evidence about these laboratories has existed for some time, but has been completely ignored despite Russia raising it publicly many times." The core question here is not "whether evidence exists" but "the mechanism by which evidence is credited": whose information counts and whose does not — that threshold is itself a geopolitical issue.

The third is the possibility of policy change. Jones suggests that if it is ultimately established that "this was a clear policy direction of U.S. funding for biological laboratories that could ultimately be used for military operations," then "there may be some real changes" in U.S. policy. The core variable here is whether the condition "usable for military operations" holds — and that is precisely the hardest part to confirm.

The Structural Roots of the Transparency Deficit

The timing of this declassification deserves attention. Gabbard was appointed by Trump, and the Trump administration's diplomatic framework "seeks a negotiated settlement of the Ukraine crisis" — within that framework, publicly exposing contested elements of the U.S. role in the Ukraine situation can be read as a variant of diplomatic pressure: sometimes showing your negotiating counterpart your hand is more effective than hiding it.

From a longer structural perspective, the controversy rooted in the United States maintaining an extensive, military-linked biological laboratory network across so many countries lies not in the specific purposes the laboratories serve, but in the fact that this network has operated outside international oversight for years. Any country maintaining a large-scale network of research facilities abroad that handles dangerous pathogens and receives military funding would provoke similar questions. This is a structural critique that no "good guys/bad guys" narrative framework can dissolve.

Gabbard's own statement generalized the phenomenon: "The Biden administration's national security team lied to the American people about the existence of U.S.-funded biological laboratories and threatened those who tried to expose the truth." Whether or not one agrees with such forceful wording, the phenomenon she points to — a government agency failing for years to provide adequate transparency on a major international issue bearing on public safety — is a judgment of fact.